Julianne Bruno currently leads CRISPR Tx’s lead program in hemoglobinopathies focused on beta-thalassemia and sickle cell disease. In her previous role in New Product Planning at CRISPR, Julianne led the development of a commercial launch strategy across both the hemoglobinopathy and I/O portfolio. Before joining CRISPR, Julianne worked at McKinsey & Company where she was a leader in the biotech practice and served a number of biotechnology companies on a wide range of commercial topics. Julianne received her MBA from The Wharton School and also holds an A.B. from Princeton University.